Gene expression alterations in chronic hypoxic MCF7 breast cancer cell line

Genomics

Volumn 104, Issue 6, 2014, Pages 477-481

  Hamdan, Feda' H ^a   Zihlif, Malek A ^a  

^a THE UNIVERSITY OF JORDAN   (Jordan)

Author keywords

Cancer biomarkers; Chronic hypoxia; Doxorubicin chemoresistance; Hepatocyte nuclear factor 4

Indexed keywords

ADENOSINE A2B RECEPTOR; BIOLOGICAL MARKER; CYCLIN G2; DOXORUBICIN; EARLY GROWTH RESPONSE FACTOR 1; ENDOTHELIN 1; GELATINASE B; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; HEME OXYGENASE 1; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; INITIATION FACTOR 4E BINDING PROTEIN 1; ORNITHINE DECARBOXYLASE; OXYGEN; PLACENTAL GROWTH FACTOR; PROTEIN DNAJ; PROTEIN KINASE PIM 1; PROTEIN LYSINE 6 OXIDASE; THIOREDOXIN INTERACTING PROTEIN; VASCULOTROPIN A; HEPATOCYTE NUCLEAR FACTOR 4; HNF4A PROTEIN, HUMAN;

ADORA2B GENE; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BTG1 GENE; CCNG2 GENE; CELL HYPOXIA; CELL PROLIFERATION; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DDIT4 GENE; DNAJC5 GENE; EDN1 GENE; EGR1 GENE; EIF4EBP1 GENE; GENE; GENE EXPRESSION; HMOX1 GENE; HNF4A GENE; HUMAN; HUMAN CELL; INCUBATION TIME; MCF 7 CELL LINE; MTT ASSAY; NDRG1 GENE; ODC1 GENE; PGF GENE; PIM1 GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SLC2A1 GENE; SLC2A3 GENE; TIME; TXNIP GENE; UPREGULATION; VEGFA GENE; BREAST TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

BREAST NEOPLASMS; CELL HYPOXIA; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE NUCLEAR FACTOR 4; MCF-7 CELLS; OXYGEN; UP-REGULATION;

EID: 84918790491     PISSN: 08887543     EISSN: 10898646     Source Type: Journal    
DOI: 10.1016/j.ygeno.2014.10.010     Document Type: Article

References (44)

1. F. Bray, (2004).
2. Kim Y., Lin Q., Glazer P.M., Yun Z. Hypoxic tumor microenvironment and cancer cell differentiation. Curr. Mol. Med. 2009, 9:425-434.
3. Vaupel P., Thews O., Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med. Oncol. 2001, 18:243-259.
4. Vaupel P., Mayer A., Briest S., Hockel M. Hypoxia in breast cancer: role of blood flow, oxygen diffusion distances, and anemia in the development of oxygen depletion. Adv. Exp. Med. Biol. 2005, 566:333-342.
5. Becker A., Stadler P., Lavey R.S., Hansgen G., Kuhnt T., Lautenschlager C., Feldmann H.J., Molls M., Dunst J. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 2000, 46:459-466.
6. Ward C., Langdon S.P., Mullen P., Harris A.L., Harrison D.J., Supuran C.T., Kunkler I.H. New strategies for targeting the hypoxic tumour microenvironment in breast cancer. Cancer Treat. Rev. 2013, 39:171-179.
7. Rademakers S.E., Span P.N., Kaanders J.H., Sweep F.C., van der Kogel A.J., Bussink J. Molecular aspects of tumour hypoxia. Mol. Oncol. 2008, 2:41-53.
8. Alqawi O., Wang H.P., Espiritu M., Singh G. Chronic hypoxia promotes an aggressive phenotype in rat prostate cancer cells. Free Radic. Res. 2007, 41:788-797.
9. Bando H., Toi M., Kitada K., Koike M. Genes commonly upregulated by hypoxia in human breast cancer cells MCF-7 and MDA-MB-231. Biomed. Pharmacother. 2003, 57:333-340.
10. Bayer C., Vaupel P. Acute versus chronic hypoxia in tumors: controversial data concerning time frames and biological consequences. Strahlenther. Onkol. 2012, 188:616-627.
11. Sullivan R., Pare G.C., Frederiksen L.J., Semenza G.L., Graham C.H. Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Mol. Cancer Ther. 2008, 7:1961-1973.
12. Wilson W.R., Hay M.P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 2011, 11:393-410.
13. Rohwer N., Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist. Updat. 2011, 14:191-201.
14. Doublier S., Belisario D.C., Polimeni M., Annaratone L., Riganti C., Allia E., Ghigo D., Bosia A., Sapino A. HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast. BMC Cancer 2012, 12:4.
15. Wouters A., Pauwels B., Lardon F., Vermorken J.B. Review: implications of in vitro research on the effect of radiotherapy and chemotherapy under hypoxic conditions. Oncologist 2007, 12:690-712.
16. Chen N., Chen X., Huang R., Zeng H., Gong J., Meng W., Lu Y., Zhao F., Wang L., Zhou Q. BCL-xL is a target gene regulated by hypoxia-inducible factor-1{alpha}. J. Biol. Chem. 2009, 284:10004-10012.
17. Nahta R., Yuan L.X., Fiterman D.J., Zhang L., Symmans W.F., Ueno N.T., Esteva F.J. B cell translocation gene 1 contributes to antisense Bcl-2-mediated apoptosis in breast cancer cells. Mol. Cancer Ther. 2006, 5:1593-1601.
18. Shoshani T., Faerman A., Mett I., Zelin E., Tenne T., Gorodin S., Moshel Y., Elbaz S., Budanov A., Chajut A., Kalinski H., Kamer I., Rozen A., Mor O., Keshet E., Leshkowitz D., Einat P., Skaliter R., Feinstein E. Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol. Cell. Biol. 2002, 22:2283-2293.
19. Schwarzer R., Tondera D., Arnold W., Giese K., Klippel A., Kaufmann J. REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase. Oncogene 2005, 24:1138-1149.
20. Chang B., Liu G., Yang G., Mercado-Uribe I., Huang M., Liu J. REDD1 is required for RAS-mediated transformation of human ovarian epithelial cells. Cell Cycle 2009, 8:780-786.
21. Rodriguez-Enriquez S., Carreno-Fuentes L., Gallardo-Perez J.C., Saavedra E., Quezada H., Vega A., Marin-Hernandez A., Olin-Sandoval V., Torres-Marquez M.E., Moreno-Sanchez R. Oxidative phosphorylation is impaired by prolonged hypoxia in breast and possibly in cervix carcinoma. Int. J. Biochem. Cell Biol. 2010, 42:1744-1751.
22. Wohlkoenig C., Leithner K., Deutsch A., Hrzenjak A., Olschewski A., Olschewski H. Hypoxia-induced cisplatin resistance is reversible and growth rate independent in lung cancer cells. Cancer Lett. 2011, 308:134-143.
23. Ke Q., Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol. Pharmacol. 2006, 70:1469-1480.
24. Tsuchiya T., Kominato Y., Ueda M. Human hypoxic signal transduction through a signature motif in hepatocyte nuclear factor 4. J. Biochem. 2002, 132:37-44.
25. Zhang W., Tsuchiya T., Yasukochi Y. Transitional change in interaction between HIF-1 and HNF-4 in response to hypoxia. J. Hum. Genet. 1999, 44:293-299.
26. Maglione D., Guerriero V., Viglietto G., Delli-Bovi P., Persico M.G. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:9267-9271.
27. Fischer C., Mazzone M., Jonckx B., Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?. Nat. Rev. Cancer 2008, 8:942-956.
28. Hedlund E.M., Hosaka K., Zhong Z., Cao R., Cao Y. Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:17505-17510.
29. Odorisio T., Schietroma C., Zaccaria M.L., Cianfarani F., Tiveron C., Tatangelo L., Failla C.M., Zambruno G. Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability. J. Cell Sci. 2002, 115:2559-2567.
30. Marcellini M., De Luca N., Riccioni T., Ciucci A., Orecchia A., Lacal P.M., Ruffini F., Pesce M., Cianfarani F., Zambruno G., Orlandi A., Failla C.M. Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor. Am. J. Pathol. 2006, 169:643-654.
31. Van de Veire S., Stalmans I., Heindryckx F., Oura H., Tijeras-Raballand A., Schmidt T., Loges S., Albrecht I., Jonckx B., Vinckier S., Van Steenkiste C., Tugues S., Rolny C., De Mol M., Dettori D., Hainaud P., Coenegrachts L., Contreres J.O., Van Bergen T., Cuervo H., Xiao W.H., Le Henaff C., Buysschaert I., Kharabi Masouleh B., Geerts A., Schomber T., Bonnin P., Lambert V., Haustraete J., Zacchigna S., Rakic J.M., Jimenez W., Noel A., Giacca M., Colle I., Foidart J.M., Tobelem G., Morales-Ruiz M., Vilar J., Maxwell P., Vinores S.A., Carmeliet G., Dewerchin M., Claesson-Welsh L., Dupuy E., Van Vlierberghe H., Christofori G., Mazzone M., Detmar M., Collen D., Carmeliet P. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 2010, 141:178-190.
32. Schomber T., Kopfstein L., Djonov V., Albrecht I., Baeriswyl V., Strittmatter K., Christofori G. Placental growth factor-1 attenuates vascular endothelial growth factor-A-dependent tumor angiogenesis during beta cell carcinogenesis. Cancer Res. 2007, 67:10840-10848.
33. Bjorndahl M., Cao R., Eriksson A., Cao Y. Blockage of VEGF-induced angiogenesis by preventing VEGF secretion. Circ. Res. 2004, 94:1443-1450.
34. De Falco S. The discovery of placenta growth factor and its biological activity. Exp. Mol. Med. 2012, 44:1-9.
35. Green C.J., Lichtlen P., Huynh N.T., Yanovsky M., Laderoute K.R., Schaffner W., Murphy B.J. Placenta growth factor gene expression is induced by hypoxia in fibroblasts: a central role for metal transcription factor-1. Cancer Res. 2001, 61:2696-2703.
36. Torry R.J., Tomanek R.J., Zheng W., Miller S.J., Labarrere C.A., Torry D.S. Hypoxia increases placenta growth factor expression in human myocardium and cultured neonatal rat cardiomyocytes. J. Heart Lung Transplant. 2009, 28:183-190.
37. Sands M., Howell K., Costello C.M., McLoughlin P. Placenta growth factor and vascular endothelial growth factor B expression in the hypoxic lung. Respir. Res. 2011, 12:17.
38. Khaliq A., Dunk C., Jiang J., Shams M., Li X.F., Acevedo C., Weich H., Whittle M., Ahmed A. Hypoxia down-regulates placenta growth factor, whereas fetal growth restriction up-regulates placenta growth factor expression: molecular evidence for "placental hyperoxia" in intrauterine growth restriction. Lab. Invest. 1999, 79:151-170.
39. Ahmed A., Dunk C., Ahmad S., Khaliq A. Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen-a review. Placenta 2000, 21(Suppl. A):S16-S24.
40. Kim K.J., Cho C.S., Kim W.U. Role of placenta growth factor in cancer and inflammation. Exp. Mol. Med. 2012, 44:10-19.
41. Scherbakov A.M., Lobanova Y.S., Shatskaya V.A., Krasil'nikov M.A. The breast cancer cells response to chronic hypoxia involves the opposite regulation of NF-kB and estrogen receptor signaling. Steroids 2009, 74:535-542.
42. Chen C.L., Chu J.S., Su W.C., Huang S.C., Lee W.Y. Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1alpha, GLUT1, and CAIX. Virchows Arch. 2010, 457:53-61.
43. Larsen M., Tazzyman S., Lund E.L., Junker N., Lewis C.E., Kristjansen P.E., Murdoch C. Hypoxia-induced secretion of macrophage migration-inhibitory factor from MCF-7 breast cancer cells is regulated in a hypoxia-inducible factor-independent manner. Cancer Lett. 2008, 265:239-249.
44. Greijer A.E., de Jong M.C., Scheffer G.L., Shvarts A., van Diest P.J., van der Wall E. Hypoxia-induced acidification causes mitoxantrone resistance not mediated by drug transporters in human breast cancer cells. Cell. Oncol. 2005, 27:43-49.